Methods: Samples from consecutive patients that presented to endoscopy unit, University Malaya Medical Centre, Kuala Lumpur from July 2011 to Jan 2013 were obtained for culture and sensitivity testing. Four gastric biopsies of patients (two from antrum and two from the body of the stomach) were obtained from H. pylori-positive patients. Resistance to individual antibiotics were tested using the Etest. Results from treatment naive patients Ku-0059436 in vivo were analysed in this study. Results: Total of 119 samples were obtained. The median age of patients was 56.0 (Range: 14–77). The male : female ratio was 65:54. Prevalence of resistance to

metronidazole was 39/119 (32.8%). No female (24/65) [36.9%] versus male (15/54) [27.8%] difference in frequency of metronidazole resistance was noted (p = 0.290). Resistance rate for clarithromycin and levofloxacin was 9/119 (7.6%) and 7/119 (5.9%) respectively. There was zero resistance to amoxicillin, nitrofurantoin, tetracycline and rifampicin. Four strains had dual resistance to clarithromycin and metronidazole. Two strains had

dual resistance to clarithromycin and levofloxacin and 2 were resistant to metronidazole and levofloxacin. Conclusion: The emergence of resistance to levofloxacin and clarithromycin are worrying and needs to be closely monitored. The high resistance to metronidazole is in keeping with our previous observations. Key Word(s): 1. H.pylori resistance; MCE公司 2. levofloxacin; 3. clarithromycin; 4. Triple therapy; Presenting Author: ASADIZZIDDIN DAJANI Additional JQ1 Authors: ADNANM ABU HAMMOUR, MOHAMMEDALI EL NOUNOU, MOHAMMEDABDULLAH ZAKARIA Corresponding Author: ASADIZZIDDIN DAJANI Affiliations: ADSC; AMC Objective: Current eradication rates of H. pylori achieved by the

standard triple therapy alone are below 70% worldwide. A recent prospective study that was done on 2011 in the UAE revealed that the current eradication rate is (67.9%). This is believed to be related to clarithromycin and metronidazole resistance. The use of probiotics as adjuvants to H. pylori treatment appeared to be an attractive alternative that may improve cure rates. This was indicated from several in vitro studies that showed lactobacilli or their cell-free cultures to inhibit or kill H. pylori, prevent its adhesion to mammalian epithelial cells and prevent IL8 release. Hence probiotics emerged as a useful adjunctive agent used both in the treatment and probably prophylaxis of H. pylori infections. Methods: To explore methods of restoring the earlier success rates that had been reported by our group (95%) between the years 1994 and 2000, several protocols were set with a view to decide on the role of probiotics as adjuvants on improving the currently used common conventional protocols.